Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives

被引：100

作者：

Zhu, Andrew X. ^{[1
]}

机构：

[1] Harvard Univ, Ctr Canc, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA

来源：

SEMINARS IN ONCOLOGY | 2012年 / 39卷 / 04期

关键词：

ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; RECEPTOR TYROSINE KINASES; PROGNOSTIC-SIGNIFICANCE; FACTOR-ALPHA; OPEN-LABEL; ANTITUMOR-ACTIVITY; TUMOR PROGRESSION; EXPRESSION; BEVACIZUMAB;

D O I：

10.1053/j.seminoncol.2012.05.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：493 / 502

页数：10

共 65 条

[1]

Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial [J].

Abou-Alfa, Ghassan K. ;

Johnson, Philip ;

Knox, Jennifer J. ;

Capanu, Marinela ;

Davidenko, Irina ;

Lacava, Juan ;

Leung, Thomas ;

Gansukh, Bolorsukh ;

Saltz, Leonard B. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (19) :2154-2160

[2]

Alberts SR, 2011, AM J CLIN ONCOL

[3]

Role of tyrosine kinase inhibitors in cancer therapy [J].

Arora, A ;

Scholar, EM .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979

[4]

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma - Results of a multicenter phase 2 study [J].

Asnacios, Amani ;

Fartoux, Laetitia ;

Romano, Olivier ;

Tesmoingt, Chloe ;

Louafi, Samy S. ;

Mansoubakht, Touraj ;

Artru, Pascal ;

Poynard, Thierry ;

Rosmorduc, Olivier ;

Hebbar, Mohamed ;

Taieb, Julien .

CANCER, 2008, 112 (12) :2733-2739

[5]

A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas [J].

Bekaii-Saab, Tanios ;

Markowitz, Joseph ;

Prescott, Nichole ;

Sadee, Wolfgang ;

Heerema, Nyla ;

Wei, Lai ;

Dai, Zunyan ;

Papp, Audrey ;

Campbell, Angela ;

Culler, Kristy ;

Balint, Catherine ;

O'Neil, Bert ;

Lee, Ruey-min ;

Zalupski, Mark ;

Dancey, Janet ;

Chen, Helen ;

Grever, Michael ;

Eng, Charis ;

Villalona-Calero, Miguel .

CLINICAL CANCER RESEARCH, 2009, 15 (18) :5895-5901

[6]

Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study [J].

Bitzer, Michael ;

Horger, Marius ;

Ganten, Tom M. ;

Siveke, Jens T. ;

Woerns, Marcus A. ;

Dollinger, Matthias M. ;

Gerken, Guido ;

Scheulen, Max E. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)

[7]

EXPRESSION AND BIOSYNTHETIC VARIATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN HEPATOCELLULAR CARCINOMA-DERIVED CELL-LINES [J].

CARLIN, CR ;

SIMON, D ;

MATTISON, J ;

KNOWLES, BB .

MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (01) :25-34

[8]

Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG) [J].

Chan, Stephen Lam ;

Chung, Hyun Cheol ;

Wang, Ling-Zhi ;

Lim, Robert S. C. ;

Picus, Joel ;

Boyer, Michael J. ;

Erlichman, Charles ;

Chan, Anthony T. C. ;

Goh, Boon C. ;

Yeo, Winnie .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)

[9]

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery [J].

Chao, Y ;

Li, CP ;

Chau, GY ;

Chen, CP ;

King, KL ;

Lui, WY ;

Yen, SH ;

Chang, FY ;

Chan, WK ;

Lee, SD .

ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (04) :355-362

[10]

Chen L, 2009, J CLIN ONCOL S, V27, p15s

← 1 2 3 4 5 6 7 →